ConductScience.org, home

Paper ยท 34930786

Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.

Song K and 30 others. Cancer Discov, 2022. Cited by 72 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges. Papers, record 34930786. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34930786

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.
PubMed
Journal
Cancer Discov
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
4.22
iCite
Revised in PubMed
2024-09-23
PubMed

Authors31

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Song KKai
2Minami JKJenna K
3Huang AArthurhttps://orcid.org/0000-0001-9085-850X
4Dehkordi SRSiavash R
5Lomeli SHShirley Hhttps://orcid.org/0000-0002-0872-8309
6Luebeck JJenshttps://orcid.org/0000-0003-4391-979X
7Goodman MHMark H
8Moriceau GGatien
9Krijgsman OOscarhttps://orcid.org/0000-0003-0825-3291
10Dharanipragada PPrashanthi

1 to 10 of 31Source PubMed

See all 31 authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MelanomaMajor topic
Proto-Oncogene Proteins B-rafMajor topic
Cell Line, Tumor
Drug Resistance, Neoplasm
Humans
Mutation
Neoplasm Recurrence, Local
Oncogenes
Protein Kinase Inhibitors

Source PubMed

Grants15

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R21 CA215910NCI NIH HHSUnited StatesR21CA215910PubMed and NIHNIH RePORTER
R21 CA255837NCI NIH HHSUnited StatesR21CA255837PubMed and NIHNIH RePORTER
S10 OD016387NIH HHSUnited StatesS10OD016387PubMed and NIHNIH RePORTER
U24 CA264379NCI NIH HHSUnited StatesU24CA264379PubMed and NIHNIH RePORTER
R01 CA176111NCI NIH HHSUnited StatesR01CA176111PubMed and NIHNIH RePORTER
P50 CA211015NCI NIH HHSUnited StatesP50CA211015PubMedNIH RePORTER
T32 CA009056NCI NIH HHSUnited StatesT32CA009056PubMed and NIHNIH RePORTER
P01 CA244118NCI NIH HHSUnited StatesP01CA244118PubMed and NIHNIH RePORTER
P01 CA168585NCI NIH HHSUnited StatesP01CA168585PubMedNIH RePORTER
R01 CA222877NCI NIH HHSUnited StatesR01CA222877PubMed and NIHNIH RePORTER

1 to 10 of 15

See all 15 grants

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References122

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,027,500FaNDOM: Fast nested distance-based seeding of optical maps.Patterns (N Y)2021https://conductscience.org/library/papers/34027500PubMed
21,422,048Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. 1978.Biotechnology1992https://conductscience.org/library/papers/1422048PubMed
328,595,656ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.Mol Cancer2017https://conductscience.org/library/papers/28595656PubMed
422,113,612RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).Nature2011https://conductscience.org/library/papers/22113612PubMed
52,189,894Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells.J Clin Invest1990https://conductscience.org/library/papers/2189894PubMed
66,285,209Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line.Nature1982https://conductscience.org/library/papers/6285209PubMed
731,569,279Double-strand breakage in the extrachromosomal double minutes triggers their aggregation in the nucleus, micronucleation, and morphological transformation.Genes Chromosomes Cancer2020https://conductscience.org/library/papers/31569279PubMed
824,055,054Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.Cell Rep2013https://conductscience.org/library/papers/24055054PubMed
931,068,700Next-generation characterization of the Cancer Cell Line Encyclopedia.Nature2019https://conductscience.org/library/papers/31068700PubMed
10281,704Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexate-resistant Chinese hamster ovary cell line.Proc Natl Acad Sci U S A1978https://conductscience.org/library/papers/281704PubMed

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
42,929,807Extrachromosomal DNA: A New Therapeutic Frontier for Overcoming Cancer Drug Resistance.Cells2026https://conductscience.org/library/papers/42929807PubMed
42,888,240AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes.Nat Methods2026https://conductscience.org/library/papers/42888240PubMed
42,864,811A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42864811PubMed
42,816,857Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer.Mol Cancer2026https://conductscience.org/library/papers/42816857PubMed
42,791,387Unraveling the lexicon of complex mutational phenomena in human cancers.Nat Cancer2026https://conductscience.org/library/papers/42791387PubMed
42,706,270scAmp enables focal gene amplification analysis from single-cell data.Nat Commun2026https://conductscience.org/library/papers/42706270PubMed
42,702,596Plasticity of extrachromosomal DNA segregation during drug adaptation.Nat Commun2026https://conductscience.org/library/papers/42702596PubMed
42,412,795Detecting and reconstructing breakage-fusion-bridge cycles from long-read sequencing using BFBArchitect.Bioinformatics2026https://conductscience.org/library/papers/42412795PubMed
42,094,063Extrachromosomal DNA Gives Cancer a New Evolutionary Pathway.Res Sq2026https://conductscience.org/library/papers/42094063PubMed
41,997,126A recipe for chaos: Extrachromosomal DNA and the hallmarks of cancer.Cell2026https://conductscience.org/library/papers/41997126PubMed

1 to 10 of 62

See all 62 cited by

Genes28

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34930786

GET https://conductscience.org/api/papers/v1/34930786/authors?page=2